Aileron Therapeutics, Inc. (Aileron)

Oncology Corporate Profile

HQ Location

281 Albany Street
Cambridge, MA 2139

Company Description

Aileron Therapeutics is a clinical stage biopharmaceutical company that is developing first-in-class therapeutics based on its proprietary stapled peptide drug platform. Aileron's lead drug candidate is ALRN-6924, a p53 re-activator for the treatment of cancer, and is currently in clinical testing. As an industry leader in stabilized peptides, Aileron aims to dramatically improve the treatment of a wide range of diseases including cancer, endocrine/metabolic disorders and infectious diseases.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ALRN-6924p53 activatorIVarious cancer types

View additional information on product candidates here »


Recent News Headlines

There are no news items to display